Ximelagatran versus warfarin in the prevention of atrial fibrillation-related stroke: Both sides of the story [10]

Stroke

Volumn 38, Issue 7, 2007, Pages

  Testa, Luca ^a   Van Gaal, William ^a   Agostoni, Pierfrancesco ^b   Abbate, Antonio ^c   Trotta, Graziana ^d   Biondi Zoccai, Giuseppe G L ^e  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MELAGATRAN; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LETTER; LIVER TOXICITY; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; HUMANS; WARFARIN;

EID: 34347359723     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.486969     Document Type: Letter

References (10)

1. Akins PT, Feldman HA, Zoble RG, Newman D, Spitzer SG, Diener HC, Albers GW. Secondary stroke prevention with Ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and SPORTIF V clinical trials. Stroke. 2007;38:874-880.
2. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698.
3. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-698.
4. Testa L, Andreotti F, Biondi Zoccai GGL, Burzotta F, Bellocci F, Crea F. Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22639 patients. Int J Cardiol. 2007 (in press).
5. Testa L, Biondi-Zoccai GGL, Porto I, Andreotti F, Crea F. The direct thrombin inhibitor Ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Exp Opin Drug Metab Toxicol. 2007 (in press).
6. Testa L, Andreotti F, Trotta G, Biondi Zoccai GGL, Burzotta F, Bellocci F, Crea F. Ximelagatran/melagatran versus conventional anticoagulant therapy: meta-analysis of 13 randomised controlled trials enrolling 22639 patients. Oral Presentation for the Young Investigator Award in Thrombosis. European Society of Cardiology/World congress of Cardiology 2007.
7. AstraZeneca receives action letter from FDA for Exanta™ (ximelagatran). Available at http://fdaadvisorycommittee.com.
8. Successful outcome of the mutual recognition procedure for Exanta™ (ximelagatran) in Europe. Press release from European Agency for the Evaluation of Medicinal Products (EMEA). Available at http://www.emea.eu.int.
9. AstraZeneca Decides to Withdraw Exanta™ (ximelagatran). Press release from AstraZeneca international, February 14, 2006. Accessed February 15, 2006, at http://www.astrazeneca.com/pressrelease.
10. Registered ongoing clinical trials for Dabigatran Etexilate. Available at http://www.clinicaltrials.gov.